Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Galapagos  /  Ontwikkelingen Biofocus-DPI

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Galapagos AEX:GLPG.NL, BE0003818359

  • 27,180 19 apr 2024 17:35
  • -0,200 (-0,73%) Dagrange 26,860 - 27,280
  • 62.640 Gem. (3M) 80,1K

Ontwikkelingen Biofocus-DPI

57 Posts
Pagina: 1 2 3 »» | Laatste | Omlaag ↓
  2. forum rang 4 aossa 10 oktober 2007 10:27
    www.biofocus.com/ADME_optimization

    The BioFocus DPI ADME group (ADMEnsa) provides high quality, flexible and rapid ADME optimization services, based on a track record of success in drug discovery.

    Poor absorption, distribution, metabolism and excretion (ADME) properties are a major cause of compound failure in clinical trials. To help to resolve ADME and pharmacokinetic (PK) liabilities, ADMEnsa offers a comprehensive ADME platform supporting drug discovery projects from hit to preclinical candidate.

    Working as part of an integrated team with medicinal chemists from the BioFocus DPI medicinal chemistry group or offering comprehensive ADME support to your in-house projects, ADMEnsa provides a versatile service dedicated to helping discovery teams deliver balanced leads and pre-clinical candidates.

    BioFocus DPI is pleased to announce the opening of a new ADMEnsa unit on the US-West Coast to better serve our customers in the North American and Asia-Pacific regions.

    Benefits
    ADME/PK information is a key driver in lead identification optimization strategies. Generating appropriate ADME/PK data enables project teams to:
    • Identify optimal drug-like properties of hit and lead molecules
    • Enable efficient HTS hit prioritization
    • Guide lead optimization project synthesis
    • Have increased confidence in key decision-making on compound series progression
    • Improve the overall speed and efficiency of drug discovery
    • Deliver high quality drug candidates

    Capabilities
    Our ADME teams are led by ADME optimization experts with over 100 years of global pharma and biotech experience and a track record of successful marketed drugs. Our ADME scientists have the expertise necessary to run a wide variety of ADME assays and establish new assay protocols to resolve project-specific issues.

    Once through the discovery phase, our ADME optimization experts can also act in a consultancy role in the design of regulatory drug metabolism/pharmacokinetic studies as required to support clinical trials.

    In silico
    ADMEnsa develop and employ the unique ADMEnsa Interactive (AI) in silico optimization platform. AI enables scientists to efficiently design, profile, identify and effectively prioritise compounds to achieve an optimal balance of properties at all stages of drug discovery. This intuitive desktop interface integrates predicted and in vitro data, such as potency and selectivity measurements, enabling scientists to rapidly identify and design high quality compounds to meet their project’s objectives.

    ADMEnsa Interactive is also available for license on a non-exclusive basis.

    In vitro
    ADMEnsa offer a comprehensive range of in vitro ADME assays at competitive rates, whether occasionally submitting small numbers of compounds or large batches of compounds on a frequent basis. Our consultants review all data generated, to provide expert interpretation and recommendations in a comprehensive report. Please see our ADME and Physicochemical Property Determination catalog for detailed information.

    All routine assays are performed according to validated, SOP-controlled methods monitored by our ISO9001 accredited quality control system. Client-specific protocols, additional assay formats and additional species can be adopted and validated.

    Bioanalysis
    The ADMEnsa Laboratory provides high quality bioanalysis in an extensive range of biofluids and tissue homogenates (e.g. blood, plasma, CSF, liver, brain). Mass spectrometry-based metabolite ID from in vivo samples or in vitro incubates can also be provided.

    Pharmacokinetics
    Our experienced pharmacokinetics scientists can help to design and supervise PK studies, in all major species, to address the needs of your projects. All PK samples are analyzed in our laboratory and pharmacokinetic analysis is performed with industry-standard applications WinNonLin and PK solutions. A full report is provided as standard, providing interpretation of the PK results and recommendations.

    Case study
    Please click here to download a case study illustrating how ADMEnsa can act as a ‘virtual ADME department’ to support your project from hit to candidate.


    ADMEnsa™ and ADMEnsa Interactive™ are trademarks of Galapagos NV and/or its affiliates
  3. forum rang 4 aossa 10 oktober 2007 10:38
    Noot: ADMEnsa komt voort uit de acquisitie van Inpharmatica.

    Bericht uit 2006:
    www.biopendium.com/news/2006/140306.htm

    www.bioportfolio.com/biotech_news/Inp...

    Licenties:
    www.bioscreening.net/2006/12/06/wyeth...

    www.biofocus.com/news/item/Admensa_In...

    Voor wie Japans begrijpt:
    www.pharmadesign.co.jp/products/admen...
  4. forum rang 4 aossa 10 oktober 2007 10:51
    More to read:
    crucell.yourbb.nl/viewtopic.php?p=530...

    Or:
    Voor de wetenschappers:
    www.biofocus.com/In_silico_optimization

    En voor wie Japans begrijpt (of studeert):
    www.pharmadesign.co.jp/products/admen...
    ------------------------------------------
    Folders:
    www.biofocus.com/page/downloads/ADMEn...
    www.biofocus.com/page/downloads/ADMEn...
  5. [verwijderd] 10 oktober 2007 17:56
    quote:

    stappa schreef:

    Op de biofocus DPI site vandaag een bericht naar buiten gebracht.
    In mijn optiek een verdere optimalisering en uitbreiding van het DPI service gedeelte. Conform de outlook van 2007. Gala is op koers!!

    www.biofocus.com/page/downloads/ADMEn...

    gr
    Stappa
    scherp,Stappa(AB!)

    groet,
    patrick
  6. [verwijderd] 10 oktober 2007 17:57
    quote:

    aossa schreef:

    More to read:
    crucell.yourbb.nl/viewtopic.php?p=530...

    Or:
    Voor de wetenschappers:
    www.biofocus.com/In_silico_optimization

    En voor wie Japans begrijpt (of studeert):
    www.pharmadesign.co.jp/products/admen...
    ------------------------------------------
    Folders:
    www.biofocus.com/page/downloads/ADMEn...
    www.biofocus.com/page/downloads/ADMEn...
    weer wat te lezen in deze rustige tijd...
    dank aossa!(AB!)

    groet,Patrick
  7. [verwijderd] 10 oktober 2007 18:01
    14 March 2006

    Commenting on the release, John Lisle, CEO of Inpharmatica, said:

    “These new editions of Admensa Interactive are a direct response to user feedback on one of our most successful offerings. We expect these enhancements both to provide even better solutions for our pharmaceutical and biotechnology customers’ discovery needs, and to reinforce Inpharmatica’s leading position in the marketplace.”

    www.biopendium.com/news/2006/140306.htm

    een verdere verbetering dus,wat weer tot betere en snellere onderzoekresultaten zal lijden.
  10. [verwijderd] 7 april 2008 18:51
    7 April 2008

    BioFocus DPI launches ‘Intelligent Screening’ platform at SBS
    New approach to accelerating drug discovery programs
    BioFocus DPI is launching a new approach to discovery biology at the Society for
    Biomolecular Sciences Annual Conference taking place this week in St. Louis. Called
    ‘Intelligent Screening’, this approach focuses on combining the know-how and
    expertise of BioFocus DPI’s scientists with extensive high-throughput and
    information-rich screening capabilities to generate faster results and accelerate
    partners’ drug discovery programs.
    According to Dr. Katherine Hilyard, Vice President of Biological Sciences at BioFocus DPI, “As the
    name Intelligent Screening implies, we are promoting an intelligence-led approach to discovery
    biology. This means harnessing our considerable screening experience within a wide range of
    target classes and disease areas to develop customized, biologically-relevant assays for partners’
    discovery programs. This is in contrast with alternative approaches such as running numerous
    high-volume, high-throughput tests where the likelihood of identifying compounds with the
    desired biological activity is low.”
    In shaping its Intelligent Screening approach, BioFocus DPI calls upon: PrimePathTM, its
    compound screening service that uses disease-relevant complex assays in human primary cells;
    its high-throughput and information-rich ion channel screening capabilities; and its natural
    product screening platform, which is ideal for addressing difficult targets, such as protein-protein
    interactions. Furthermore, these services are complemented by BioFocus DPI’s world-class
    screening libraries.
    More information about using this Intelligent Screening approach in hit finding, hit-to-lead and
    lead optimization campaigns can be found at www.biofocusdpi.com.
    About BioFocus DPI
    BioFocus DPI’s aim is to expand partners’ drug pipeline by accelerating the gene-to-candidate
    discovery process. This is achieved through a comprehensive discovery platform, which includes
    target discovery in human primary cells, focused as well as diverse compound libraries, in vitro
    and cell-based screening, medicinal chemistry and ADME/PK services, supported by unique
    chemogenomic and informatics tools. As the service division of Galapagos, BioFocus DPI has
    over 300 employees in five countries worldwide.
    CONTACT:
    Katherine Hilyard, PhD
    Vice President of Biological Sciences, BioFocus DPI
    Tel: +44 1799 533500
    kate.hilyard@glpg.com
    BioFocus® and PrimePath ™ are trademarks of Galapagos NV and/or its affiliates

    www.biofocus.com/page/downloads/IS_PR...

    gr

    Stappa
  11. [verwijderd] 8 april 2008 18:21
    BioFocus is weer op dreef. Wederom een nieuw bericht, wel lastig om op waarde te bepalen.

    8 April 2008

    BioFocus DPI releases five new compound libraries
    BioFocus DPI today introduces new FieldFocus and SoftFocus libraries that were
    created with advanced modeling tools. The libraries consist of novel drug-like
    compounds specifically targeted towards kinases and voltage-dependent ion
    channels. These targets represent two of the most important and commonly studied
    protein classes for drug discovery. Two new lead-like ThemePair Fragment libraries
    from BioFocus DPI are also being released.
    Following the success of the FieldFocus ion channel libraries, BioFocus DPI is introducing its first
    FieldFocus kinase (FFK) libraries. The FFK01 and FFK02 libraries have been designed using a
    new in silico, fragment-based approach to tackle kinase library design from a ligand perspective,
    complementing the highly successful SoftFocus kinase libraries.
    BioFocus DPI is also releasing its latest SoftFocus ion channel (SFI) library. SFI08 contains
    approximately 500 compounds designed to target voltage-dependent ion channels. These
    libraries were created using BioFocus DPI’s proprietary chemogenomic tool Helical Domain
    Recognition Analysis, which has been proven to generate potent and selective hit series.
    Two new ThemePair Fragment (TPF) libraries are also now available from BioFocus DPI. The
    TPF10 library contains lead-like compounds substituted with a single heavy atom and are
    designed for use in X-ray crystallographic screening. The TPF11 library is based on nine bicyclic
    scaffolds suitable for both conventional bioassays as well as high-throughput affinity screening.
    “We are constantly evolving the design tools used in the production of our focused libraries and
    the latest FieldFocus kinase libraries are an exciting new addition to our portfolio,” said Richard
    Hill, Director Discovery Products, BioFocus DPI.
    CONTACT
    Richard Hill, PhD
    Director, Discovery Products, BioFocus DPI
    Tel: +44 1799 533 500
    richard.hill@glpg.com
    More about FieldFocus kinase (FFK) libraries
    FieldFocus is a ligand centered approach to library design based around molecular fields. The
    FFK libraries have been designed using a new in silico, fragment-based approach. Using virtual
    fragment screening and Cresset Biomolecular’s FieldAlign technology, this approach has been
    applied to find suitable matches between a series of fragments and the bioactive conformation of
    a potent kinase inhibitor, thereby tackling kinase library design from a ligand perspective.
    More about SoftFocus ion channel (SFI) libraries
    SFI libraries are created using BioFocus DPI’s proprietary Helical Domain Recognition Analysis
    (HDRA) chemogenomic tool. HDRA links X-ray data, sequence alignment and SAR data and is
    used to rationalize scaffold binding in the pore region of ion channels and to guide monomer
    selection. This design method has proved remarkably successful with the first generation of
    SoftFocus ion channel libraries (SFI01-07) delivering potent and selective compound series
    against a variety of ion channel drug targets.
    More about ThemePair Fragment (TPF) libraries
    TPF libraries primarily target kinases, but are applicable to other protein targets such as
    proteases. These lead-like compounds have a lower molecular weight and cLogP than the
    SoftFocus libraries. With their enhanced predicted solubility these compounds are suitable for
    conventional bioassay or affinity-based screening.
    About BioFocus DPI
    BioFocus DPI’s aim is to expand partners’ drug pipeline by accelerating the gene-to-candidate
    discovery process. This is achieved through a comprehensive discovery platform, which includes
    target discovery in human primary cells, focused as well as diverse compound libraries, in vitro
    and cell-based screening, medicinal chemistry and ADME/PK services, supported by unique
    chemogenomic and informatics tools. As the service division of Galapagos, BioFocus DPI has
    over 300 employees in five countries worldwide. For more information about BioFocus DPI,
    please visit www.biofocusdpi.com.
    BioFocus®, SoftFocus®, SFI™, FieldFocus™, FFKTM, ThemePair™ and Helical Domain Recognition Analysis™
    are trademarks of Galapagos NV and/or its affiliates

    www.biofocus.com/page/downloads/Apr08...

    gr

    Stappa
  12. [verwijderd] 8 april 2008 21:09
    wedreom scherp,Stappa.
    ik kijk met 1 oog naar galapagos,zit er in voor de LT.
    koers gaat al een paar dagen up,maar m.i. slaat de koers helemaal nergens op,maar ik heb het volste vertrouwen in de toekomst met een veel hogere koers.
    er wordt hard gewerkt aan de diversen lopende onderzoeken,die in galop vorderen,ze doen hun naam eer aan!
    er zullen de nodige milestone betalingen binnen gehaald worden dit jaar en verder verwacht ik binnenkort "de deal" in het bot-metastase onderzoek.

    groet,patrick
  13. [verwijderd] 20 mei 2008 17:50
    Biofocus DPI in the picture:

    CALIFORNIA STEM CELL AND BIOFOCUS DPI TO COLLABORATE IN
    ALS ASSOCIATION-FUNDED RESEARCH USING HUMAN MOTOR NEURONS
    MOTORPLATE™ 96 Assay-Ready Well Plates Enable High Throughput and High
    Content Screening Assays

    California Stem Cell, Inc. (CSC) will supply international drug discovery organization
    BioFocus DPI, the service division of Galapagos, with its MOTORPLATE™ 96 assayready
    well plates, containing motor neuron progenitors (MNPs) derived from human
    embryonic stem cells (hESC). BioFocus DPI will use the high purity, clinical grade
    human motor neurons to perform assay development and screening for amyotrophic
    lateral sclerosis (ALS or “Lou Gehrig’s Disease”) drug discovery on behalf of The ALS
    Association’s TREAT ALS™ drug discovery and clinical trials program.
    “BioFocus DPI chose to source human motor neurons from CSC because its multi-well plate
    format enables us to develop specialized high-throughput assays not previously possible,” said
    Katherine Hilyard, PhD, Vice President of Biological Sciences, BioFocus DPI. “This the first source
    of high purity human motor neurons available for use in high-content screening assays. This
    significant advancement allows us to develop innovative human cell-based assays for the
    discovery of drugs for ALS and other neurological disorders.”
    The ALS Association’s TREAT ALS (Translational Research Advancing Therapy for ALS) program is
    funding this collaborative research project as part of its global initiative to speed the discovery of
    new drugs and therapies for ALS.
    “The ALS Association is focused on accelerating new and promising developments from the
    laboratory bench into treatments for ALS,” said Lucie Bruijn, PhD, science director and vice
    president of The ALS Association. “The unique ability of CSC to generate human motor neurons
    on a large scale, and the target discovery engine provided by BioFocus DPI, will contribute to the
    development of medicines that may significantly slow the progression of this disease and
    ultimately lead to a cure.”
    “CSC is delighted to help our lead customer BioFocus DPI to accelerate its drug discovery
    programs, and to begin to supply the marketplace with stem cell derived human motor neurons,
    produced using state of the art, proprietary and commercially scalable manufacturing processes.
    The potential market for this product in high-throughput and high-content screening analyses for
    predictive toxicology and drug discovery is very significant,” said Dr. Chris Airriess, Chief
    Operating Officer, CSC. “More importantly, CSC is proud to work toward the common mission of
    developing a treatment for ALS.”
    About BioFocus DPI
    BioFocus DPI aims to expand its partners’ drug pipelines by accelerating the gene-to-candidate
    discovery process. This is achieved through a comprehensive discovery platform, which includes
    target discovery in human primary cells, focused as well as diverse compound libraries, in vitro
    and cell-based screening, medicinal chemistry and ADME/PK services, supported by unique
    chemogenomic and informatics tools. As the service division of Galapagos, BioFocus DPI has over
    300 employees in five countries worldwide.
    About California Stem Cell, Inc
    California Stem Cell, Inc. is a privately held company focused on the manufacturing of high-purity
    human cells for therapeutic development and clinical application. Since its founding in 2005, CSC
    has developed and has intellectual property surrounding methods for scalable production of
    human motor neurons, neuronal progenitors, cardiac muscle and sino-atrial node cells at its
    Irvine, Calif. facility. CSC is currently in the pre-clinical development stage of stem cell based
    therapies for amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s Disease), spinal muscular
    atrophy (SMA), spinal cord injury (SCI) and coronary heart disease.
    About The ALS Association
    The ALS Association is a leader in ALS research and the only national not-for-profit voluntary
    health organization dedicated solely to the fight against ALS. The mission of The ALS Association
    is to lead the fight to cure and treat ALS through global cutting-edge research, and to empower
    people with Lou Gehrig’s Disease and their families to live fuller lives by providing them with
    compassionate care and support.
    CONTACTS
    BioFocus DPI
    Katherine Hilyard, PhD
    Tel: +44 1799 533500
    kate.hilyard@glpg.com
    California Stem Cell, Inc.
    Chris Airriess, PhD
    Tel.: +1 949 534 9149
    chris@californiastemcell.com
    The ALS Association
    Gary Wosk
    Tel: +1 818 587 2241
    gwosk@alsa-natio

    www.biofocus.com/page/downloads/CSC_B...

    Gr
    Stappa
  14. [verwijderd] 1 juli 2008 23:35
    De agenda vwb upcoming events(keurig op tijd ge-update overigens waarvoor de complimenten) blijft goed gevuld...
    www.biofocusdpi.com/

    UPCOMING EVENTS


    JUNE 2008

    26 June

    How guided decision making with StarDrop software can transform drug discovery

    Matt Segall and Elaine Tate speaking

    Live StarDrop webcast

    Register here



    29 June - 4 July

    Wellcome Trust Advanced Course:

    Practical Aspects of Small Molecule Drug Discovery

    Cambridge (UK)

    David Cronk and Alan Beresford speaking

    JULY 2008

    2-4 July
    International Conference on Medicinal Chemistry

    Angers (France)

    AUGUST 2008

    4-7 August

    Drug Discovery and Development of Innovative Therapeutics (DDT)

    Boston, MA (USA)

    Onno van de Stolpe speaking

    8-10 August

    Huntington's Disease: 2008

    Cambridge, MA (USA)

    31 August - 4 September

    International Symposium on Medicinal Chemistry (ISMC)

    Vienna (Austria)

    SEPTEMBER 2008



    8-10 September 2008

    Small Molecule Drug Discovery Summer School

    Industry’s focus on drug targets

    Downing College (UK)

    John Overington speaking



    24-26 September

    Assays and Cellular Targets (ACT)

    San Diego, CA (USA)

    OCTOBER 2008



    6-8 October

    IQPC Compound Libraries

    Dϋsseldorf (Germany)

    BioFocus DPI presenting



    12-14 October

    BioPartnering Europe

    London (UK)



    14-16 October

    MipTec

    Basel (CH)

    Matthew Segall presenting

    20-24 October

    Discovery on Target

    Boston, MA (USA)

    Richard Janssen speaking



    26-29 October

    AusBiotech 2008 National Conference

    Melbourne (AUS)

    NOVEMBER 2008

    17-19 November

    American Association for Pharmaceutical Scientists (AAPS) Annual Meeting

    Atlanta, GA (USA)

  15. [verwijderd] 11 september 2008 17:57
    Klein PB'tje BioFocus DPI

    11 September 2008

    BioFocus DPI, the service division of Galapagos, and the Institute for OneWorld Health, a non-profit pharmaceutical company, announced today that it had expanded its 2006 collaboration in diarrheal disease drug discovery.

    OneWorld Health and BioFocus DPI expand collaboration to develop
    new drugs for the treatment of childhood diarrheal diseases

    BioFocus DPI to perform high-throughput screening
    BioFocus DPI, the service division of Galapagos, and the Institute for OneWorld
    Health, a non-profit pharmaceutical company, announced today that it had expanded
    its 2006 collaboration in diarrheal disease drug discovery.
    Under the expanded collaboration, BioFocus DPI is performing a high-throughput, cell-based
    functional screen to identify potential new drugs for the treatment of diarrheal diseases. The
    “hits” identified in this screen will be confirmed through a series of activity assays developed by
    BioFocus DPI specifically for this drug target.
    In 2006, BioFocus DPI and the Institute for OneWorld Health initiated a collaboration to develop
    new drugs against childhood diarrheal disease in developing countries. During this initial
    collaboration, cell based functional assays have been developed by BioFocus DPI to find small
    molecule compounds with potential activity against a specific diarrheal disease target. In a
    separate partnership initiated by OneWorld Health with Roche in April 2008, OneWorld Health
    gained access to the Roche corporate collection of compounds, with the goal of using these
    compounds in screens as starting points to discover new therapies to treat childhood diarrhea.
    Under the expanded collaboration announced today, BioFocus DPI is screening 700,000 of these
    compounds on behalf of OneWorld Health in the cell-based functional assays developed by
    BioFocus DPI to identify inhibitors of the specific target.
    Diarrheal diseases kill approximately two million children under the age of five in developing
    countries each year, which is more than the combined pediatric death toll due to AIDS,
    tuberculosis and malaria.
    “We are very pleased to continue our alliance with OneWorld Health and to work with them to
    discover drugs to these neglected childhood diseases,” said Dr. Kate Hilyard, VP Biological
    Sciences, BioFocus DPI. “By applying the assays that we have developed for this diarrheal target
    against compounds from the Roche corporate collection, we aim to make significant advances in
    the identification of a broad pipeline of drug leads to treat these diseases.”
    “BioFocus DPI’s high-throughput capabilities played a key role in our ability to access Roche’s
    compound library,” said Dr. Susan Wilson, Senior Director of the Institute for OneWorld Health’s
    Diarrheal Disease Program. “We are hopeful that through the combined efforts of these groups
    we increase our chances of finding a more effective treatment for childhood diarrheal diseases.”
    About BioFocus DPI
    BioFocus DPI aims to expand its partners’ drug pipelines by accelerating the gene-to-candidate
    discovery process. This is achieved through a comprehensive discovery platform, which includes
    target discovery in human primary cells, focused as well as diverse compound libraries, in vitro
    and cell-based screening, medicinal chemistry and ADME/PK services, supported by unique
    chemogenomic and informatics tools. As the service division of Galapagos, BioFocus DPI has over
    300 employees in five countries worldwide.
    About the Institute for OneWorld Health
    The Institute for OneWorld Health, the first US nonprofit pharmaceutical company, develops safe,
    effective and affordable new medicines for people with infectious diseases in the developing
    world. The Institute for OneWorld Health, headquartered in San Francisco, California, USA, is a
    tax-exempt 501 (c) (3) US corporation.
    CONTACTS
    BioFocus DPI
    Katherine Hilyard, PhD
    Tel: +44 1799 533500
    kate.hilyard@glpg.com
    Institute for OneWorld Health
    James H. Hickman
    Tel: +1 415 403 6317
    JHickman@oneworldhealth.org
  20. [verwijderd] 13 september 2008 13:09
    Te vroeg? Het aandeel staat zeer laag gewaardeerd, dus ik denk dat dit wel een mooie instapprijs is.

    En wat ik bedoelde met de vorige post, t'is jammer dat Galapagos, ondanks de goeie prestaties en de toch wel goede cijfers, zo weinig aandacht krijgt.

    In deze 'sombere' tijden mogen ze ook wel eens wat moeite doen om diegene die het wel goed doen, eens in de schijnwerpers te zetten.

    Moet niet altijd over Fortis en Tomtom gaan...(sterk overdreven wel :))
57 Posts
Pagina: 1 2 3 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Weinig houvast voor beleggers in Galapagos

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Galapagos Nieuws

  1. 12 apr KBC Securities verlaagt koersdoel Galapagos naar 50 euro
  2. 05 apr Galapagos toont innovatieve aanpak in hematologische kankerzorg
  3. 23 feb AEX op de waakvlam het weekend in, koersdreun Besi, Alfen en Galapagos 2
  4. 23 feb Beursblik: gebrek aan opwaarts potentieel voor Galapagos op korte termijn
  5. 23 feb Gaat AEX op recordjacht of gaat de beursweek uit als een nachtkaars?
  6. 23 feb Update : Galapagos voldoet aan verwachtingen
  7. 19 feb Beursblik: cashburn belangrijk voor Galapagos
  8. 15 feb Galapagos presenteert nieuwe onderzoeksdata op EBMT-EHA bijeenkomst
  9. 01 feb Galapagos rondt Jyseleca-transactie af
  10. 04 jan Galapagos in zee met Thermo Fisher

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!